C.M. Bidwell & Associates’s Intellia Therapeutics NTLA Stock Holding History

C.M. Bidwell & Associates’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$154	Hold	12	–	–	﹤0.01%	476
2025 Q4	$108	Hold	12	–	–	﹤0.01%	480
2025 Q3	$207	Hold	12	–	–	﹤0.01%	482
2025 Q2	$113	Hold	12	–	–	﹤0.01%	444
2025 Q1	$85	Hold	12	–	–	﹤0.01%	438
2024 Q4	$140	Hold	12	–	–	﹤0.01%	481
2024 Q3	$247	Sell	12 -1,697	-99%	-$39.1K	﹤0.01%	495
2024 Q2	$38.2K	Buy	1,709 +282	+20%	+$6.71K	0.03%	242
2024 Q1	$39.3K	Buy	1,427 +1,415	+11,792%	+$39.3K	0.03%	238
2023 Q4	$366	Sell	12 -39	-76%	-$1.12K	﹤0.01%	463
2023 Q3	$1.61K	Hold	51	–	–	﹤0.01%	489
2023 Q2	$2.08K	Hold	51	–	–	﹤0.01%	471
2023 Q1	$1.9K	Hold	51	–	–	﹤0.01%	476
2022 Q4	$1.78K	Buy	51 +39	+325%	+$1.85K	﹤0.01%	462
2022 Q3	$1K	Hold	12	–	–	﹤0.01%	457
2022 Q2	$1K	Hold	12	–	–	﹤0.01%	464
2022 Q1	$1K	Buy	+12	New	+$1.02K	﹤0.01%	501

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

C.M. Bidwell & Associates's NTLA Position: Q1 2026 in Review

C.M. Bidwell & Associates held its Intellia Therapeutics (NTLA) position steady in Q1 2026 at 12 shares worth $154. The position accounts for ﹤0.01% of the portfolio, ranked #476.

C.M. Bidwell & Associates first reported a position in NTLA in Q1 2022 and has held it in 17 quarters since. The position peaked at $39.3K in Q1 2024. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

C.M. Bidwell & Associates held 12 shares of Intellia Therapeutics worth $154 as of Q1 2026.
C.M. Bidwell & Associates left its Intellia Therapeutics share count unchanged in Q1 2026.
Intellia Therapeutics made up ﹤0.01% of C.M. Bidwell & Associates's portfolio in Q1 2026, its #476 holding.
C.M. Bidwell & Associates first reported a position in Intellia Therapeutics in Q1 2022 and has held it in 17 quarters since.
C.M. Bidwell & Associates's Intellia Therapeutics position peaked at $39.3K in Q1 2024.
302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.